Lexicon Pharma

$2.03 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Lexicon Pharma

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatments for human disease. The Company's drug programs include Sotagliflozin and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development. The Company’s LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company intends to initiate a Phase IIa clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic (DPN) pain. Its Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease.

Stock Analysis

last close $2.03
1-mo return 25.3%
3-mo return -5.6%
avg daily vol. 668.92T
52-week high 6.33
52-week low 1.31
market cap. $218M
forward pe -
annual div. -
roe -73.6%
ltg forecast -
dividend yield -
annual rev. $0M
inst own. 83.8%
baraka

Subscribe now for daily local and international financial news

Subscribe